Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic troid carcinoma (ATC)[1].
[1]. Jaume Capdevila, et al. PD-1 Blockade in Anaplastic Troid Carcinoma. J Clin Oncol. 2020 Aug 10;38(23):2620-2627.
















